What did the FDA do in 2016 based on the data about niacin?
The FDA removed the approval of combinations of statins with niacin in 2016 based on the evidence that demonstrated in multiple populations that harms and burdens outweighed benefits, and that patients and providers were likely to find niacin unacceptable due to its significant increase in adverse events and lack of benefit in clinical outcomes.